- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.10. | Cannara Biotech Inc (2): Cannara expands Curaleaf supply deal to $34-million | 1 | Stockwatch | ||
| 05.10. | Curaleaf Holdings Inc (2): Cannara expands Curaleaf supply deal to $34-million | 10 | Stockwatch | ||
| 11.09. | Cannara Biotech Inc (2): Cannara increases credit facility to $80-million | 2 | Stockwatch | ||
| 01.09. | Cannara Biotech Inc (2): Cannara Biotech appoints Fozard CFO | 1 | Stockwatch | ||
| CANNARA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 01.09. | Nicholas Fozard wird neuer Finanzvorstand bei Cannara Biotech | 1 | Investing.com Deutsch | ||
| 01.09. | Cannara Biotech names Nicholas Fozard as chief financial officer | 2 | Investing.com | ||
| 13.08. | Cannara Biotech Inc (2): Cannara arranges automatic share purchase plan | 1 | Stockwatch | ||
| 22.07. | Cannara Biotech Inc (2): Cannara gets OK from TSX for NCIB | 1 | Stockwatch | ||
| 22.07. | Cannara Biotech Inc.: Cannara Announces Normal Course Issuer Bid | 2 | GlobeNewswire (USA) | ||
| 15.07. | Cannara Q3 2026 slides: revenue climbs 16% as cash flow drops | 2 | Investing.com | ||
| 15.07. | Cannara Biotech Reports Q3 2026 Results: Full Earnings Call Transcript | 1 | Benzinga.com | ||
| 15.07. | Cannara Biotech Inc.: Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion | 391 | GlobeNewswire (Europe) | Delivered strong Q3 financial results: Generated $31.8 million in total net revenues, $13.4 million in gross profit before fair value adjustments, or 42% of revenues, $8.5 million in adjusted EBITDA1... ► Artikel lesen | |
| 15.07. | Cannara Biotech reports Q3 results | 3 | Seeking Alpha | ||
| 15.07. | Cannara Biotech Inc (2): Cannara Biotech, Curaleaf sign supply agreement | 2 | Stockwatch | ||
| 15.07. | Curaleaf Holdings Inc (2): Cannara Biotech, Curaleaf sign supply agreement | 2 | Stockwatch | ||
| 14.07. | Stocks in Play: Cannara Biotech Inc. | 1 | Baystreet.ca | ||
| 08.07. | Cannara Biotech Inc (2): Cannara Biotech to release Q3 results on July 15 | 1 | Stockwatch | ||
| 02.07. | Cannara Biotech Inc (2): Cannara obtains Canadian rights to Ampersand technology | 1 | Stockwatch | ||
| 02.07. | Cannara Biotech Inc.: Cannara Secures Exclusive Canadian Rights to Blue River's Ampersand Live Rosin Infusion Technology | 972 | GlobeNewswire (Europe) | MONTREAL, July 02, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. ("Cannara", the "Company", "us" or "we") (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade... ► Artikel lesen | |
| 07.05. | Cannara Biotech Inc (2): Cannara Biotech closes Medican Organic acquisition | 1 | Stockwatch |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 35,005 | -0,06 % | Abbvie oder Novo Nordisk: Welche Pharma-Aktie überzeugt jetzt mehr? | AbbVie und Novo Nordisk zählen zu den bedeutenden Unternehmen der globalen Pharmabranche, verfolgen jedoch unterschiedliche Wachstumsstrategien. Während AbbVie mit neuen Medikamenten den Verlust früherer... ► Artikel lesen | |
| AURORA CANNABIS | 3,520 | -0,28 % | Aurora Rejects Curaleaf's Higher Bid, But the Takeover Fight Isn't Over | ||
| CANOPY GROWTH | 0,641 | +0,85 % | Trump's Marijuana Order Is Stuck at the DEA. Here's What That Means for Canopy Growth. | ||
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: STADA launches Virustad in Germany - based on Enzymatica's ColdZyme technology | STADA has launched the oral spray Virustad in the German pharmacy market. Virustad is built on Enzymatica's clinically documented ColdZyme® technology. The launch follows the partnership agreement signed... ► Artikel lesen | |
| TILRAY BRANDS | 2,735 | +1,11 % | Tilray's Q1 Results Show A Company Transformed | ||
| INNOCAN PHARMA | 1,170 | 0,00 % | Innocan Pharma: Was der Online-Verkauf jetzt verändert | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| CRONOS GROUP | 2,898 | -0,89 % | Cronos Group Inc: Cronos Group completes CanAdelaar acquisition | ||
| SYNBIOTIC | 0,139 | -4,67 % | EQS-Adhoc: SYNBIOTIC SE: Antrag auf Eröffnung eines Insolvenzverfahrens | EQS-Ad-hoc: SYNBIOTIC SE / Schlagwort(e): Insolvenz
SYNBIOTIC SE: Antrag auf Eröffnung eines Insolvenzverfahrens
16.10.2026 / 16:13 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| DIGICANN VENTURES | 0,007 | 0,00 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,809 | 0,00 % | Aurora Cannabis: Organigram funkt Curaleaf dazwischen | ||
| GREEN THUMB INDUSTRIES | 5,680 | +2,90 % | President Trump's Push to Reschedule Marijuana Hit a Snag. Is Green Thumb Still a Buy? | ||
| SNDL | 1,112 | -2,03 % | SNDL Inc.: SNDL Announces 2026 Annual and Special Shareholders Meeting Results, Select Preliminary Third Quarter Results and Capital Return Initiatives | ||
| CRESCO LABS | 0,547 | -0,18 % | Cresco Labs Inc: Cresco Labs to release Q3 2026 results Nov. 6 | ||
| NOVERIS HEALTH SCIENCES | 0,032 | 0,00 % | Noveris Health Sciences Inc.: Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual... ► Artikel lesen |
Das Unternehmen CANNARA BIOTECH INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,260 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANNARA BIOTECH INC finden Sie auf Wallstreet Online.